Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 2874 | 318 |
09:34 ET | 240 | 315.741 |
09:36 ET | 2391 | 315.9501 |
09:39 ET | 631 | 316.3 |
09:48 ET | 300 | 316 |
09:50 ET | 945 | 315.87 |
09:52 ET | 200 | 315.83 |
09:54 ET | 1600 | 315.75 |
09:56 ET | 1500 | 316.24 |
09:57 ET | 300 | 316.335 |
10:01 ET | 800 | 316.44 |
10:03 ET | 200 | 315.94 |
10:06 ET | 1827 | 315.905 |
10:08 ET | 100 | 315.53 |
10:10 ET | 3404 | 315.76 |
10:14 ET | 526 | 315.29 |
10:19 ET | 300 | 315.525 |
10:21 ET | 500 | 315.09 |
10:24 ET | 1430 | 314.94 |
10:26 ET | 441 | 315.65 |
10:28 ET | 1346 | 315.26 |
10:30 ET | 315 | 315.195 |
10:32 ET | 400 | 315.2 |
10:35 ET | 1755 | 315.605 |
10:37 ET | 300 | 315.64 |
10:39 ET | 570 | 316.095 |
10:46 ET | 1395 | 316.64 |
10:48 ET | 300 | 316.65 |
10:50 ET | 100 | 317 |
10:51 ET | 800 | 317.395 |
10:53 ET | 100 | 317.376 |
10:55 ET | 771 | 317.825 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 14.1B | 15.0x | +8.22% |
Biomarin Pharmaceutical Inc | 15.6B | 77.8x | --- |
Beigene Ltd | 15.7B | -19.2x | --- |
Neurocrine Biosciences Inc | 14.1B | 38.1x | +62.04% |
Medpace Holdings Inc | 12.6B | 41.9x | +35.10% |
Exact Sciences Corp | 7.8B | -32.3x | --- |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.1B |
---|---|
Revenue (TTM) | $2.5B |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.56 |
EPS | $21.13 |
Book Value | $127.23 |
P/E Ratio | 15.0x |
Price/Sales (TTM) | 5.7 |
Price/Cash Flow (TTM) | 12.8x |
Operating Margin | 50.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.